Skip to content

ICLRClinical research services for pharma and biotech

ICON

By

Updated

Not investment advice. Kevin may own this stock. How we value stocks

History
Price
$186.71
Discount category
Close to intrinsic value
Analysts
Leaning bullish
Next earnings
Feb 17 · · estimated
Pick status
Research only

In short

Thesis
The market doubts the accounts and the growth of ICON after its revenue restatement and a period of falling revenue, and strong bookings that turn into revenue growth in 2027 can lift its value.
Gap
Can close. The Q4 2026 report with its 2027 guidance, expected in February 2027, and a 2026 Form 20-F filed on time show whether revenue grows again and investors can trust the accounts.

Company guidance: 2026 revenue $8,100 to $8,200 million; adjusted diluted earnings per share $10.35 to $10.65 (, Q3 2026 results release (6-K))

Price history

About

ICON plc (ICON) is based in Dublin, Ireland. It is a contract research organization (CRO). It runs clinical trials and gives development, consulting and post-marketing services to pharmaceutical, biotechnology and medical device companies and to government and public health organizations. It had about 40,250 employees in 98 locations in 55 countries at September 30, 2026.

Revenue was $2,024.8 million in Q3 2026 and $6,122.2 million for nine months, and backlog was $24.5 billion at September 30, 2026. The ordinary shares trade on Nasdaq in US dollars. ICON is a foreign private issuer: it files an annual report on Form 20-F and its quarterly reports on Form 6-K, not 10-K and 10-Q reports.

Thesis

The price of ICON depends on whether investors trust its reported numbers again, whether its strong bookings turn into revenue growth and whether its profit margin recovers. In February 2026 ICON said that its Audit Committee was investigating its accounting practices, and in April 2026 the investigation found that revenue was overstated in 2023 and 2024. ICON restated those years and the first nine months of 2025, reported material weaknesses and filed its 2025 Form 20-F late, on May 27, 2026. During the same review, ICON changed its policy on cancellations.

This cut its reported backlog by $3.9 billion, from about $25.0 billion to $21.1 billion at October 1, 2025, which is about 16% less. The cut changed the way ICON counts backlog, and ICON said that it did not change how awards enter backlog. Backlog was $24.5 billion at September 30, 2026. Revenue fell 2.9% in Q3 2026 and adjusted diluted earnings per share fell to $2.66 from $3.20, but net business wins were $3,150 million, a book-to-bill of 1.56 times.

Profit margin is the second part of the case. ICON's adjusted EBITDA margin was 20.4% in 2023 and in 2024 (restated), 18.6% in 2025 and 16.6% in Q3 2026. Revenue is almost flat, so a return of the margin toward 20% would raise earnings more than revenue growth would. Management points to better business mix, cost discipline and its AI-enabled digital platform as the ways to do this.

Peers show the size of the gap. In Q3 2026, IQVIA reported an adjusted EBITDA margin of 23.3% ($1,032 million on revenue of $4,428 million) and revenue growth of 8.0%. Medpace reported an EBITDA margin of 24.0% and revenue growth of 8.5%. Charles River reported a non-GAAP operating margin of 23.0% and revenue growth of 4.7% on an organic basis, which is a different measure of profit.

ICON reported 16.6% and a revenue decline of 2.9%. Each company defines its own measures, so compare the direction and not the last digit. For the price to hold or rise, five things must be true. ICON must fix its material weaknesses with no new restatement.

The backlog of $24.5 billion must turn into revenue growth in 2027 with few cancellations. The adjusted EBITDA margin must keep rising from 16.6%. Pharmaceutical and biotechnology customers must keep their research and development budgets. The securities class actions must not lead to large costs.

The bull case is that AI tools make drug discovery faster, so more drug candidates reach clinical trials, and ICON can run those trials with its own AI tools at lower cost. This is an argument, not a fact: no ICON report shows it in revenue yet. The Q4 2026 report, expected in February 2027, with its 2027 guidance, is the next test.

Checkpoints

  1. Feb 17, 2027 · est.Pending
    Q4 2026 results and 2027 guidanceRevenue for 2026 is in the range of $8,100 million to $8,200 million, the 2027 guidance shows revenue growth and the Q4 2026 adjusted EBITDA margin is above the 16.6% of Q3 2026, and this passes; revenue below the range, a guided decline or a lower margin fails.
  2. Apr 2027 · est.Pending
    2026 annual report on Form 20-FICON files its 2026 Form 20-F on time with no new restatement and reports progress on its material weaknesses, and this passes; a late filing or a new restatement fails.

Every passed and failed checkpoint across all picks

Recent events

  • October 27, 2026ICON reported Q3 2026 results. Revenue fell 2.9% to $2,024.8 million, adjusted EBITDA was $336.9 million and adjusted diluted earnings per share were $2.66. Net business wins were $3,150 million and backlog was $24.5 billion. ICON updated its 2026 guidance to revenue of $8,100 million to $8,200 million and adjusted diluted earnings per share of $10.35 to $10.65. The board increased the total share repurchase authorization to $750.0 million.
  • August 13, 2026ICON issued $2.15 billion of senior unsecured notes due 2029, 2031 and 2036. It used the proceeds to repay its $900 million term loan, redeem its $750 million of notes due May 2027 and repay its $500 million bridge facility.
  • June 26, 2026The lead plaintiffs in the securities class actions against ICON filed a second amended complaint, which adds the current Chief Financial Officer and a former employee as defendants.
Show 3 older events
  • May 27, 2026ICON filed its 2025 annual report on Form 20-F with restated results for 2023, 2024 and the first nine months of 2025. Before this, Nasdaq had sent a notice that ICON did not comply with its rule on timely filing. In its Q4 2025 release on the same day, ICON said that a new policy on cancellations cut its reported backlog by $3.9 billion to $21.1 billion at October 1, 2025, and that its adjusted EBITDA margin was 18.6% for 2025 and 15.5% for Q4 2025.
  • April 29, 2026The Audit Committee completed its investigation. It found that revenue was overstated in 2023 and 2024 by less than 2% each year, and ICON said that it will restate those years and the first nine months of 2025.
  • February 12, 2026ICON announced an investigation by its Audit Committee into its accounting practices, which started in late October 2025, and withdrew its 2025 guidance.

Latest news and filings

Last earnings
October 27, 2026
Next earnings
Expected about February 17, 2027. The company has not confirmed the date.
  • 6-KInterim report for the period ended Sep 30, 2026Filed iclr-20260930
  • 6-KInterim report for the period ended Jun 30, 2026Filed iclr-20260630
  • 6-KInterim report for the period ended Mar 31, 2026Filed iclr-20260331
  • 20-FAnnual report for the period ended Dec 31, 2025Filed iclr-20251231

Every filing on SEC EDGAR (CIK 1060955)

Risks

  • Trust in the accounts is low. ICON restated its results for 2023, 2024 and the first nine months of 2025 and reported material weaknesses in its internal control over financial reporting. A new error could cause another restatement or a late filing.
  • Lawsuits can cost money. Securities class actions filed in 2025 name ICON, its former Chief Executive Officer, its former Chief Financial Officer and its current Chief Financial Officer, and claim misleading statements about its financial performance.
  • Demand can fall. Revenue was down 0.3% for nine months of 2026, and cancellations were $1,584 million. Lower research budgets of customers or more cancellations would lower revenue.
  • Debt is large. Debt principal was $3,400.0 million at September 30, 2026, and ICON said that net debt was $2.6 billion. The board approved share repurchases of up to $750.0 million, which use cash that could repay debt.
  • Goodwill can be impaired again. Goodwill was $8,721.9 million at September 30, 2026, and ICON recorded a goodwill impairment of $364.2 million in Q3 2025 for its former Data Solutions reporting unit.

Key statistics

Market cap
$14B
Shares of Dec 31, 2025
52-week range
$66.57 – $219.04
To Nov 12, 2026
Beta
1.19
Vs S&P 500, 5 years monthly, to Oct 30, 2026
Average volume
973K
3 months, to Nov 12, 2026

Balance sheet

Cash
$809M
Debt
$3.4B
Net debt
$2.6B
Credit line
$500M
undrawn

Cash against debt

Cash$809M
Debt$3.4B

debt covered by cashnet debt $2.6B

When the debt is due

12 months$0.0M
Later$3.4B

The last debt is due in 2036.

At September 30, 2026, ICON had cash and cash equivalents of $809.0 million. Debt principal was $3,400.0 million, all senior unsecured notes: $750.0 million of 5.849% notes due May 2029, $500.0 million of 5.064% notes due August 2029, $1,000.0 million of 5.421% notes due August 2031, $500.0 million of 6.000% notes due May 2034 and $650.0 million of 5.995% notes due August 2036.

Earnings vs free cash flow

Fiscal 2025

  • Adjusted diluted EPS$12.53
  • Free cash flow per share$10.92

Why the two numbers differ

  • Depreciation: adds $1.97 per share. Depreciation of $156 million, without the amortization of acquired intangible assets that adjusted EPS already leaves out, is not paid in cash.
  • Capital spending: takes away $2.21 per share. ICON spent $174 million on facilities and IT infrastructure. It reports no separate software line.
  • Working capital: takes away $1.24 per share. Receivables grew by $108 million and unbilled revenue by $61 million, and unearned revenue grew by $69 million.
  • Restructuring cash: takes away $1.24 per share. Adjusted EPS leaves out restructuring costs, but the cash was paid. About $98 million is our estimate from the change in the restructuring liability.

In 2025, ICON's free cash flow was $862 million, or $10.92 per share, below its adjusted EPS of $12.53. Free cash flow is cash from operations of $1,036 million minus $174 million of capital spending, and ICON reports the same number. Stock pay is a cost in neither number's gap, because both measures add it back. The working capital cost did not come from growth: revenue grew only 0.8%, and the annual report points to the timing of billing and collection on clinical trials. In 2026 it turned around. In the nine months to September 30, 2026, working capital gave $137 million because customers prepaid, free cash flow was $682 million, or $8.82 per share, and adjusted EPS was $7.72. ICON restated its 2023 and 2024 revenue in 2026, so only 2025 and later figures are used here. GAAP EPS of $2.90 includes $465 million of impairments that did not use cash.

Dividends

ICON does not pay a dividend.

Source: company filings and market data, read on November 12, 2026.

Owners and capital return

Large holders

Percent of the shares outstanding, as each filing states it. A filing can be older than the company’s latest report.

What the company says about payouts

ICON says it has not paid cash dividends and does not currently intend to pay them in the foreseeable future. It has share repurchase programs of $750 million (February 2025) and a further $500 million (July 2025).

As of · ICON plc 2025 Form 20-F (Item 8, Dividend Policy)

Questions about ICON

What does ICON do?

ICON plc (ICON) is based in Dublin, Ireland. It is a contract research organization (CRO). Its market cap is $14B at the current price of $186.71.

When does ICON report earnings next?

This is an estimate: ICON may report on February 17, 2027. It last reported results on October 27, 2026.

Is ICON stock below its intrinsic value?

ICON stock is close to intrinsic value. This is general information, not advice.

What changed recently at ICON?

The latest update is from October 27, 2026. ICON reported Q3 2026 results.

What are the main risks for ICON?

Trust in the accounts is low. Lawsuits can cost money. Demand can fall.

How much debt and cash does ICON have?

At September 30, 2026, ICON had $3.4B of debt and $809M of cash.

Does ICON pay a dividend?

No. ICON does not pay a dividend.

Similar companies

  • TMUST-Mobile USShares: Regulation and courts, New management
    Intrinsic value
    Below intrinsic value
    Gap
    Slow
  • ERIEErie IndemnityShares: New management, Regulation and courts
    Intrinsic value
    Close to intrinsic value (AI estimate)
    Gap
    Can close
  • TLKTelkom IndonesiaShares: Regulation and courts, New management
    Intrinsic value
    Close to intrinsic value (AI estimate)
    Gap
    Slow
  • UNHUnitedHealth GroupShares: Regulation and courts, New management
    Intrinsic value
    Below intrinsic value
    Gap
    Can close
  • CTVACortevaShares: Regulation and courts, New management
    Intrinsic value
    Deep below intrinsic value
    Gap
    Slow

Loading your notes…

Read it all? Star ICLR or pass, then go on to the next one.